June 2026

Routine Data vs. Evidence Standards: The Methodological Debate Over Routine Data

Data from routine medical practice is becoming increasingly important in research. But while enthusiasm for “big data” is growing, experts and institutions such as the IQWiG are calling for methodological caution. A debate.

June 2026

States-Funded Health Insurance Financial Reform: The Conflict Between Cost Containment and Ensuring the Viability of Healthcare Facilities

The Bundestag has debated the new Statutory Health Insurance Stabilization Act. While politicians defend the austerity package, the pharmaceutical industry warns of dire consequences for Germany as a business location. An analysis.

June 2026

A System Test for Cancer Medicine: Between EU Bureaucracy and an mRNA Breakthrough

Europe is reforming its drug evaluation process, while new mRNA vaccines are making inroads into oncology. Whether these medical innovations reach patients quickly will depend on the interplay between European bureaucracy, reliable treatment data, and economic pressures on the pharmaceutical industry.

May 2026

The Gender Health Gap: Why the Future of Medicine Must Be More Female-Centric

Many diseases manifest differently in women, yet they are still often overlooked in the medical field. To ensure targeted, evidence-based treatment, women’s health must be structurally integrated into both research and clinical practice.